Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. (original) (raw)

• Journal List
• J Clin Invest
• v.101(7); 1998 Apr 1
• PMC508719

J Clin Invest. 1998 Apr 1; 101(7): 1414–1420.

R Niehues, M Hasilik, G Alton, C Körner, M Schiebe-Sukumar, H G Koch, K P Zimmer, R Wu, E Harms, K Reiter, K von Figura, H H Freeze, H K Harms, and T Marquardt

Abstract

Phosphomannose isomerase (PMI) deficiency is the cause of a new type of carbohydrate-deficient glycoprotein syndrome (CDGS). The disorder is caused by mutations in the PMI1 gene. The clinical phenotype is characterized by protein-losing enteropathy, while neurological manifestations prevailing in other types of CDGS are absent. Using standard diagnostic procedures, the disorder is indistinguishable from CDGS type Ia (phosphomannomutase deficiency). Daily oral mannose administration is a successful therapy for this new type of CDG syndrome classified as CDGS type Ib.

Full Text

The Full Text of this article is available as a PDF (354K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

• Jaeken J, De Cock P, Stibler H, Van Geet C, Kint J, Ramaekers V, Carchon H. Carbohydrate-deficient glycoprotein syndrome type II. J Inherit Metab Dis. 1993;16(6):1041–1041. [PubMed] [Google Scholar]
• Stibler H, Westerberg B, Hanefeld F, Hagberg B. Carbohydrate-deficient glycoprotein (CDG) syndrome--a new variant, type III. Neuropediatrics. 1993 Feb;24(1):51–52. [PubMed] [Google Scholar]
• Stibler H, Stephani U, Kutsch U. Carbohydrate-deficient glycoprotein syndrome--a fourth subtype. Neuropediatrics. 1995 Oct;26(5):235–237. [PubMed] [Google Scholar]
• Van Schaftingen E, Jaeken J. Phosphomannomutase deficiency is a cause of carbohydrate-deficient glycoprotein syndrome type I. FEBS Lett. 1995 Dec 27;377(3):318–320. [PubMed] [Google Scholar]
• Etchison JR, Freeze HH. Enzymatic assay of D-mannose in serum. Clin Chem. 1997 Mar;43(3):533–538. [PubMed] [Google Scholar]
• Zimmer KP, Matsuda I, Matsuura T, Mori M, Colombo JP, Fahimi HD, Koch HG, Ullrich K, Harms E. Ultrastructural, immunocytochemical and stereological investigation of hepatocytes in a patient with the mutation of the ornithine transcarbamylase gene. Eur J Cell Biol. 1995 May;67(1):73–83. [PubMed] [Google Scholar]
• Wells TN, Coulin F, Payton MA, Proudfoot AE. Phosphomannose isomerase from Saccharomyces cerevisiae contains two inhibitory metal ion binding sites. Biochemistry. 1993 Feb 9;32(5):1294–1301. [PubMed] [Google Scholar]
• Proudfoot AE, Turcatti G, Wells TN, Payton MA, Smith DJ. Purification, cDNA cloning and heterologous expression of human phosphomannose isomerase. Eur J Biochem. 1994 Jan 15;219(1-2):415–423. [PubMed] [Google Scholar]
• Stibler H, Holzbach U, Tengborn L, Kristiansson B. Complex functional and structural coagulation abnormalities in the carbohydrate-deficient glycoprotein syndrome type I. Blood Coagul Fibrinolysis. 1996 Mar;7(2):118–126. [PubMed] [Google Scholar]
• Powell LD, Paneerselvam K, Vij R, Diaz S, Manzi A, Buist N, Freeze H, Varki A. Carbohydrate-deficient glycoprotein syndrome: not an N-linked oligosaccharide processing defect, but an abnormality in lipid-linked oligosaccharide biosynthesis? J Clin Invest. 1994 Nov;94(5):1901–1909. [PMC free article] [PubMed] [Google Scholar]
• Krasnewich DM, Holt GD, Brantly M, Skovby F, Redwine J, Gahl WA. Abnormal synthesis of dolichol-linked oligosaccharides in carbohydrate-deficient glycoprotein syndrome. Glycobiology. 1995 Jul;5(5):503–510. [PubMed] [Google Scholar]
• Panneerselvam K, Freeze HH. Mannose corrects altered N-glycosylation in carbohydrate-deficient glycoprotein syndrome fibroblasts. J Clin Invest. 1996 Mar 15;97(6):1478–1487. [PMC free article] [PubMed] [Google Scholar]
• Panneerselvam K, Etchison JR, Freeze HH. Human fibroblasts prefer mannose over glucose as a source of mannose for N-glycosylation. Evidence for the functional importance of transported mannose. J Biol Chem. 1997 Sep 12;272(37):23123–23129. [PubMed] [Google Scholar]
• Körner C, Lehle L, von Figura K. Abnormal synthesis of mannose 1-phosphate derived carbohydrates in carbohydrate-deficient glycoprotein syndrome type I fibroblasts with phosphomannomutase deficiency. Glycobiology. 1998 Feb;8(2):165–171. [PubMed] [Google Scholar]
• Cleasby A, Wonacott A, Skarzynski T, Hubbard RE, Davies GJ, Proudfoot AE, Bernard AR, Payton MA, Wells TN. The x-ray crystal structure of phosphomannose isomerase from Candida albicans at 1.7 angstrom resolution. Nat Struct Biol. 1996 May;3(5):470–479. [PubMed] [Google Scholar]
• Alton G, Kjaergaard S, Etchison JR, Skovby F, Freeze HH. Oral ingestion of mannose elevates blood mannose levels: a first step toward a potential therapy for carbohydrate-deficient glycoprotein syndrome type I. Biochem Mol Med. 1997 Apr;60(2):127–133. [PubMed] [Google Scholar]
• Payton MA, Rheinnecker M, Klig LS, DeTiani M, Bowden E. A novel Saccharomyces cerevisiae secretory mutant possesses a thermolabile phosphomannose isomerase. J Bacteriol. 1991 Mar;173(6):2006–2010. [PMC free article] [PubMed] [Google Scholar]
• de la Fuente M, Peñas PF, Sols A. Mechanism of mannose toxicity. Biochem Biophys Res Commun. 1986 Oct 15;140(1):51–55. [PubMed] [Google Scholar]
• de la Fuente M, Hernanz A. Enzymes of mannose metabolism in murine and human lymphocytic leukaemia. Br J Cancer. 1988 Nov;58(5):567–569. [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation